An unbiased motif search of the transferrin promoter region showed that CP2 binds to the transferrin pro-moter, an iron-regulating protein, and regulates transferrin transcription.. Resu
Trang 1CP2 transcription factor
Sang-Min Jang1,*, Jung-Woong Kim1,*, Chul-Hong Kim1, Joo-Hee An1, Eun-Jin Kang1,
Chul Geun Kim2, Hyun-Jung Kim3and Kyung-Hee Choi1
1 Department of Life Science (BK21 Program), College of Natural Sciences, Chung-Ang University, Seoul, Korea
2 Department of Life Science and Research Institute for Natural Sciences, Hanyang University, Seoul, Korea
3 College of Pharmacy, Chung-Ang University, Seoul, Korea
Introduction
Alzheimer’s disease (AD) is a neurodegenerative
dis-ease that affects cognition, behavior and function [1]
Two major protein aggregates are associated with AD,
extracellular neuritic plaques (NP) and intracellular
neurofibrillary tangles (NFT) b-amyloid peptides (Ab)
are 40 and 42 amino acid peptides derived from
the amyloid precursor protein by the action of b- and
c-secretase, and are the major components of NPs [2]
NFTs are composed of the microtubule-associated
protein tau, which is phosphorylated by kinases such
as glycogen synthase kinase 3b (GSK3b), cAMP-dependent kinase, stress activated protein kinase (SAPK)4⁄ p38d and casein kinase 1 [3–5] Hyper-phosphorylated tau forms toxic aggregates that pre-cede NFT formation [6,7] These two aggregates induce neuronal death and synaptic loss during devel-opment of AD
Oxidative stress-related neuronal cell death has long been implicated in a number of age-associated diseases, including AD [8–10] In many cases, the rate of oxygen
Keywords
Alzheimer’s disease; CP2; iron homeostasis;
oxidative stress; transferrin
Correspondence
K.-H Choi, Department of Life Science
(BK21 Program), College of Natural
Sciences, Chung-Ang University, 221
Heuksuk Dong, Dongjak Ku, Seoul 156-756,
South Korea
Fax: +82 2 824 7302
Tel: +82 2 820 5209
E-mail: khchoi@cau.ac.kr
*These authors contributed equally to this
work
The authors declare no conflict of interest
(Received 16 February 2010, revised 28
June 2010, accepted 12 July 2010)
doi:10.1111/j.1742-4658.2010.07801.x
Accumulation of b-amyloid protein (Ab) is one of the most important pathological features of Alzheimer’s disease Although Ab induces neurode-generation in the cortex and hippocampus through several molecular mech-anisms, few studies have evaluated the modulation of transcription factors during Ab-induced neurotoxicity Therefore, in this study, we investigated the transcriptional activity of transcription factor CP2 in neuronal damage mediated by Ab (Ab1–42 and Ab25–35) An unbiased motif search of the transferrin promoter region showed that CP2 binds to the transferrin pro-moter, an iron-regulating protein, and regulates transferrin transcription Ectopic expression of CP2 led to increased transferrin expression at both the mRNA and protein levels, whereas knockdown of CP2 down-regulated transferrin mRNA and protein expression Moreover, CP2 trans-activated transcription of a transferrin reporter gene An electrophoretic mobility shift assay and a chromatin immunoprecipitation assay showed that CP2 binds to the transferrin promoter region Furthermore, the binding affinity
of CP2 to the transferrin promoter was regulated by Ab, as Ab (Ab1–42 and Ab25–35) markedly increased the binding affinity of CP2 for the trans-ferrin promoter Taken together, these results suggest that CP2 contributes
to the pathogenesis of Alzheimer’s disease by inducing transferrin expres-sion via up-regulating its transcription
Abbreviations
Ab, b-amyloid protein; AD, Alzheimer’s disease; AICD, amyloid precursor protein (APP) intra-cellular domain; ChIP, chromatin
immunoprecipitation; EMSA, electrophoretic mobility shift assay; GSK3b, glycogen synthase kinase 3b; GST, glutathion S-transferase; NFT, neurofibrillary tangle; NP, neuritic plaque; ROS, reactive oxygen species; shRNA, small hairpin RNA.
Trang 2radical production is directly related to damage to the
elements of living cells, such as proteins, DNA and
membranes [11–15] The results of a previous study
suggest that the effects of Ab accumulation induce the
production of hyperreactive oxygen species (ROS) via
production of free radicals [16] Increased oxidative
stress can promote both formation of Ab [17] and
hyperphosphorylation of tau in a manner that is
reminiscent of neurofibrillar tangles [18] Among the
many possible metabolic consequences of progressive
Ab accumulation, altered ionic homeostasis,
particu-larly excessive calcium entry into neurons, makes a
strong contribution to selective neuronal dysfunction
and death, based on studies of the effects of
aggre-gated Ab in culture [19,20]
Iron is involved in the generation of ROS by
cata-lyzing the production of OH• from hydrogen peroxide
(H2O2) via the Fenton reaction [21] Hydroxyl radicals
can damage DNA, proteins and lipids, and are
believed to be responsible for much of the cellular and
tissue injury associated with reperfusion disorders [22]
In cases of AD, redox-active iron is associated with
NPs and NFTs through participation in in situ
oxida-tion and catalysis of H2O2-dependent oxidation [23] It
is generally accepted that iron overload leads to axonal
dystrophy and necrotic or apoptotic cell death [24] In
AD, alterations of iron regulatory proteins cause an
abnormal distribution of iron in the brain Transferrin
is an iron regulatory protein that carries ferric iron
from the plasma, lymph and cerebrospinal fluid to cells
through the transferrin cycle [25] It has been reported
that transferrin is homogenously distributed around
NPs, and is found in astrocytes in the cerebral cortical
white matter of AD brain tissue [26] Moreover,
a strong immunoreactivity with the iron storage
protein ferritin was observed in NPs in AD
hippo-campuses [27]
CP2 is a transcription factor that belongs to the
Drosophila grainyhead-like gene family, and has been
found to stimulate transcription of the a-globin gene
[28] Although CP2 is expressed ubiquitously, it has
specific regulatory functions in certain types of cells In
erythrocytes, CP2 regulates a-globin expression by
binding to the CP2 binding motif CNRG-N6
-CNR(G⁄ C) in the a-globin promoter [29,30] CP2 is
also known to play pivotal roles in neural tissue
development, and it has been suggested that a
poly-morphism in the 3¢-untranslated region of the CP2
gene is associated with sporadic AD [31] Moreover,
it has been proposed that CP2 plays an important
role in Down syndrome-related AD by regulating
the expression of a trifunctional enzyme encoded by
the glycinamide ribonucleotide synthetase⁄
aminoimi-dazole ribonucleotide synthetase⁄ glycinamide ribonu-cleotide transformylase gene, which is localized to chromosome 21q22.1 within the Down syndrome critical region [32,33] However, the mechanisms of transcriptional regulation of CP2 that may play an important role in the pathology of AD have not yet been fully elucidated
In this study, we identified CP2 as a novel transcrip-tional factor that regulates transferrin expression in response to Ab An unbiased motif search of transfer-rin promoter sequences revealed that the transfertransfer-rin promoter has putative CP2 binding sequences; there-fore, the functional roles of CP2 in transferrin tran-scription were examined in vitro and in vivo These findings identify a new molecular pathway through transcription factor CP2 by which Ab increases gene transcription associated with the pathology of AD
Results
Conserved sequences of the transferrin promoter region contain CP2 binding sites
The iron regulatory protein transferrin is involved in ROS production, which causes neurotoxicity in neuro-nal cells We therefore investigated which transcription factors could regulate transcription of the transferrin gene To identify conserved sequences in the transfer-rin promoter, we first aligned the DNA sequence of the human transferrin promoter from )600 to )1, in relation to the transcriptional start site, with the corre-sponding regions of the mouse, rat, cow and horse transferrin genes Analysis using multiple sequence alignment programs revealed the presence of conserved sites at positions )179 to )1 in the transferrin pro-moter We next searched for transcription factors that are likely to recognize a binding motif in the conserved transferrin promoter sequences As shown in Fig 1A, several transcription factors were identified as putative binding factors for transferrin promoter regions includ-ing CP2, specificity protein 1 and p53 Interestinclud-ingly,
we found that the CP2 binding site was the most fre-quent motif in the conserved transferrin promoter Specifically, our analysis revealed that there are four CP2 consensus sites at positions )178 to )159, )130
to)113, )115 to )105 and )53 to )35 (Fig 1B)
Transcription factor CP2 increases the endogenous transferrin mRNA level
To determine whether CP2 is a possible transcriptional regulator of transferrin, HEK293 cells were tran-siently transfected with CP2 expression plasmids, and
Trang 3transferrin mRNA expression was analyzed by
RT-PCR As shown in Fig 2A, over-expression of CP2
significantly up-regulated transferrin transcription in a
concentration-dependent manner Moreover,
transfec-tion of CP2 small hairpin RNA (shRNA) that
effec-tively decreased the level of exogenous FLAG-tagged
CP2 proteins reduced the mRNA level of transferrin
(Fig 2A, lane 4) In addition, knockdown of
endoge-nous CP2 using its shRNA significantly reduced
trans-ferrin mRNA expression (Fig 2B) Taken together,
these results suggest that transcription of transferrin is
dependent on CP2 expression To further examine the
functional roles of CP2 in transferrin transcription,
promoter reporter assays were performed The
trans-ferrin promoter fragment from)600 to )1 was cloned,
and reporter constructs were transiently transfected
into HEK293 cells with CP2 expression plasmids In the presence of exogenous CP2, transferrin promoter activity was stimulated to a level 6.2 times greater than that of the control, and increased in a CP2 dose-dependent manner (Fig 2C) In addition, transferrin promoter activity decreased in HEK293 cells
transfect-ed with CP2 shRNA Moreover, knockdown of endog-enous CP2 protein reduced the level of transferrin reporter activation These results indicate that CP2 is able to activate the transcription of transferrin
The transferrin proximal promoter contains a CP2-response element
To determine the responding element for the CP2-med-iated expression of transferrin, we performed luciferase
CCCGTT AA T GACGCGTTTGTGT T CTCCAGTT T CTAAC GC G T CGG CC GGGA G GGAGGCACGT- ATTTCC GCT CGCC -
-CCCGTT AA T GACGCGTTTGTGT T CTCCAGTT T CTAAC GT G T CGG CC GGGA G GCACAT- ATTTCC CCT CGCC
CGGTGTCCCTCCGCCACGTCTTCGCCCAGACAGACAT -CCCGTT CG C GACGCGTTTGTGT T CCAGTT C CTAAC
A -CCCGTT CG CAT CGCGTTTGTGT C CTCCAGTT C AAC AC G A CGG GA CCCG G -CTCCT ATTTCC CCG CGCC CCGCACCCCTCCGCCGTGTCTGCGGCTAGTCAGACACGAGCGG
C ACAC T -AACAGCACCATC ACCTAAGGT AC G T AGACA G GGT G TC G AGTC C TTTACTCCACTAGT A TC- CCG T TC T TT C CTTCCCCC A CC T AC CCC A CTAA
C ACAC ACACACACCACCACCACAAACGGGACCACC ACCTAAGGT AC G T AGACA G GGT G AT AGTC C TTTACTCCACT G GT A TC- CCG T TC T TT C CTTCCCCC A CC C AC CCC G CTAA
A AC A - ACCTAAGGT GG G C AGACA A GGT C TC C AGTC C TTTACTCCACTAGT C GGG CCG C TC C TT A CTTCCCCC T-C CC G AC CCC T CTAA
A AC G G - ACCTAAGGT AG G C AGACA G GGT C TC GTC T TTTACTCCACTAGT C GAC CCG C TC C TT A CTTC A CCC T-C CC T AC TTT CC G CTAA
AcaC acctAAGGT G G C AGaca GGT Tc aGTC TTTACTCCACTaGT g CcG TC TT CTTCcCCC CC aC cCC CTAA
G ACAC G -ACC TGAGG AAGGT GA G C AG CAGA GGT C TC G AGTC T TTTACTCCACTAGT CACC- C C TC A TT C CTTCCCCC CAA CC C TC CCC G CTAA
CCCGTT cC gaCGcGTTTGTGt CtCCAGTT CtAAC g g cgg gg g atttcc cgcc
CCCGTT GGG C GACG T GTTTGTG CC CTCCAGTT T CTAAC GC G T CGG GC GTCC G GCCCTTACCTT ATTTCC CTG CGCC
CCGCGGCCTCCGA -Homo sapiens : Rattus norvegicus :
Bos taurus : Equus caballus :
–35 –53
–94
–105 –115 –113 –130
–159 –178
–193
Enhancer region Negative region –3600 –3300 –1000 –620
Promoter region
Homo sapiens : Rattus norvegicus :
Bos taurus : Equus caballus :
TCCTCGGACTCGAGTCGCCCCGTCCTTCTCCCTCGTCGAGGAGGCACCCCCTGGAAACTCTCGGGTCCTCGTCCT AAAGCTCCCTGTGGACCACCCCTCGTTTTCCACGACTCAGACAGAAACTGGAACTCGGGTCGAACAAAGAGGACG TAGGAGGGGGTTTTCCCCGAAACGGACAGTAAGACGTCAAGATCACACCCCAGACCCGCGTCAAGAAAAGGGAGA GGTCGGAGCCTCAGAAGGAGACACCTGACGCGTCTATCCTGACCACCGTGCCTGGTCGAGACGTCGGGACCTCAG TCCTCGTCTCGGGGGGCCGAGGGTCGGGCGGCATCGGCGAGGACCGTGGCTCGCTCGGCGCTACTGTTACCGACG
TAACACGAAGTACAGGGAAGGGTAGTTGTAAAGACACGACCTGAGGAAGGTGAGCGCCCAGCAGAGGTCTCGAGT CTTTTACTCCACTAGTCACCCTGCTCATTCCTTCCCCCCAACCCTCTCCCCGCTAACCCGTTGGGCCGACGTGTT TGTGCCCTCCAGTTTCTAACGCGGGTCGGGCGGGTCCGGCCCTTACCTTATTTCCCTGCGCCCCGCGGCCTCCGA
p300
Human TF Gene ID: 7018
A
B
MyoD, NKX-2.5 GATA-1, GATA-2
GATA-1, GATA-2
Fig 1 Highly conserved regions of the transferrin promoter containing putative CP2 binding motifs (A) The highly conserved region of the human transferrin gene (gene ID 7018) promoter was analyzed using the MOTIF searching program (TRANSFAC database, http://motif.gen-ome.jp) to identify possible transcription factors CP2 is the factor that appears most frequently (B) The promoter sequences for human, mouse, rat, cow and horse transferrin genes were aligned using a ClustalW multiple sequencing alignment program The conserved sequences of the transferrin promoter are indicated in gray or black according to the percentage conservation (100% black, 80% gray) Boxes indicate conserved CP2 sites (CP2 I, GGGGCAGTGAGGGGCGGTG; CP2 II, GGGCAAGCGGGAACCAGGT; CP2 III, ATCTGTTTATTTCTGGCCG; CP2 IV, CCCCAAACCAA) and their positions relative to the transcriptional start site of the human transferrin promoter are indicated CP2 III and IV overlap by 2 bp.
Trang 4reporter assays using various mutant forms of human
transferrin promoter in HEK293 cells To accomplish
this, we used three mutants from which the following
regions had been deleted: CP2 binding site I (mutant
1; mut1), CP2 binding site I, III and IV (mutant 2;
mut2), and the entire CP2 binding site (mutant 3;
mut3) (Fig 3A) As the CP2 binding site III sequence
overlaps with the CP2 binding site IV sequence by two
base pairs, we deleted these portions concurrently
(Fig 3A) As expected, the wild-type (WT) promoter
encompassing nucleotides )600 to )1 induced
lucifer-ase reporter activity in a CP2 concentration-dependent
manner, while CP2 shRNA significantly reduced this
activity (Fig 3B, lanes 1–4) However, the mut1, mut2
and mut3 promoter constructs abolished the luciferase
activity under both the CP2 over-expressed and
knock-down conditions (Fig 3B, lanes 5–16) These findings suggest that the CP2 binding site I at positions )53 to )35 is responsible for the CP2-mediated transcriptional activation of human transferrin, and imply that CP2 binds to CP2 binding site I directly or through interaction with other transcription factors to enhance transferrin gene expression in cells
CP2 binds to the transferrin promoter in vitro and in vivo
To confirm whether CP2 binds directly to CP2 bin-ding site I in the proximal promoter region of trans-ferrin, we performed an electrophoretic mobility shift assay (EMSA) using glutathion S-transferase (GST)-tagged recombinant CP2 protein An oligonucleotide
FLAG-CP2 :
1
TF GAPDH
CP2 shRNA :
mRNA ratio of TF/GAPDH 0.0 0.5 1.0 1.5 2.0
**
TF
GAPDH
mRNA ratio of TF/GAPDH
0.0 0.4 0.7 1.0
**
FLAG-CP2 β-tubulin
CP2 shRNA :
0 2 4 6 8 10
TF-luc
**
TF-luc
Endo CP2 β-tubulin
0 0.5 1.0
**
Fig 2 Transcription factor CP2 increases the endogenous transferrin mRNA level (A) Total RNA from HEK293 cells transfected with plas-mids expressing FLAG-tagged CP2 and ⁄ or CP2 shRNA was analyzed by RT-PCR using transferrin- and GAPDH-specific primers The level of GAPDH was used as a loading control Representative images of agarose gels are shown (upper panels) and band intensity was measured Normalized transferrin levels were calculated relative to GAPDH (bottom panel) (B) HEK293 cells were transiently transfected with CP2 shRNA RNA was extracted, and RT-PCR analysis was performed as in (A) (C) Lysates from HEK293 cells transfected with increasing amounts of plasmids encoding CP2 DNA, transferrin promoter–luciferase or CP2 shRNA vectors were analyzed for luciferase activity All data were normalized to b-galactosidase activity Data are expressed as fold increases compared to the control (upper panel) The expression lev-els of proteins were assessed by immunoblotting (bottom panlev-els) Expression of b-tubulin was included as a loading control (D) HEK293 cells were co-transfected with transferrin promoter–luciferase and pCMV-b-galactosidase with/without CP2 shRNA Luciferase activity was measured 48 h after transfection and normalized to b-galaosidase activity The expression levels of proteins were assessed by immunoblot-ting using CP2 antibody All data are representative of three independent experiments, and statistical significance was determined using Tukey’s post hoc test (**P < 0.01).
Trang 5encompassing the consensus CP2 binding site I at
posi-tions )63 to )24 of the human transferrin promoter
was used as a probe for EMSA As shown in Fig 4A,
addition of CP2 produced a slower-migrating DNA–
protein complex in a dose-dependent manner (lanes 4
and 5), whereas the GST protein, used as a control,
did not form a DNA–protein complex (lanes 2 and 3)
The presence of CP2 in the protein–DNA complex
was verified by adding CP2 antibody Addition of the
CP2 antibody supershifted a portion of the CP2
com-plex (lane 6), but use of IgG as a negative control
did not alter the binding pattern (lane 7) The
trans-ferrin probe–CP2 protein–CP2 antibody complex
dis-appeared when cold transferrin probes were added as
competitors (lane 8)
To further confirm CP2 binding to the region of the
transferrin promoter in vivo, we performed a
chroma-tin immunoprecipitation assay (ChIP) in HT22 cells, a
mouse hippocampal cell line, using CP2 antibody
Prior to the ChIP assay, we observed endogenous CP2
protein expression by Western analysis in HT22 cells
(data not shown) Binding of CP2 to the transferrin
promoter was examined by PCR using appropriate primers Normal rabbit serum used as a negative control did not immunoprecipitate the transferrin pro-moter, whereas CP2 antibody precipitated a region of the transferrin promoter that contains the CP2 binding sequences (Fig 4B) These results (Fig 4A,B) clearly indicate that CP2 induces transferrin transcription by directly binding to the transferrin promoter
Ab induces transcriptional activity of CP2 by enhancing its binding affinity to the transferrin promoter
It has been reported that Ab regulates the transcrip-tional activity of several classic transcription factors, including nuclear factor-jB and activator protein-1 [34,35] These observations raise the possibility that Ab modulates the transcriptional activity of CP2 To determine whether the transcriptional activity of CP2 can be modulated by Ab, HT22 cells were transiently transfected with luciferase reporter plasmids containing the CP2-responsive element of the human transferrin
TF promoter
A
B
–600
+1
–600
–600
–600
–600
–188
Control –600 ~ –1 Mutant 1 –600 ~ –82
Mutant 2 –600 ~ –131
Mutant 3 –600 ~ –188
0 2 4 6 8 10 12 14
FLAG-CP2 : CP2 shRNA :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
FLAG-CP2 β-tubulin
**
Fig 3 The transferrin proximal promoter region contains a CP2 response element (A) Transferrin promoter constructs used in transactiva-tion studies Various mutants of human transferrin promoters were used, and are indicated as a mutant 1, mutant 2 and mutant 3 The method used for mutation of transferrin promoters is described in Experimental procedures (B) Each of the constructs shown in (A) and pCMV-b-galactosidase were transiently transfected into the HEK293 cells, together with increasing amounts of plasmids encoding CP2 DNA
or CP2 shRNA vectors At 48 h after transfection, cells were lysed and subjected to luciferase assays Data were normalized against b-galac-tosidase activity and are expressed as the relative luciferase units compared to the control The level of CP2 expression in each group of cells was confirmed by Western blotting, an example of which is shown (bottom panel) Expression of b-tubulin was used as a loading control All data are representative of three independent experiments, and statistical significance was determined using Tukey’s post hoc test (**P < 0.01; n.s., not significant).
Trang 6promoter Forty-eight hours after transfection, cells
were treated with Ab (Ab1–42: 0, 50 and 100 nm; Ab25–35:
0, 5, 10 and 20 lm) for an additional 12 h As shown
in Fig 5A, Ab1–42 treatment increased the level of
transferrin transcripts by up to 3.5-fold compared
with the control (lane 1), while knockdown of CP2
reduced Ab-induced transferrin–luciferase activities (lanes 5 and 6) Ab25–35 treatment also increased CP2-mediated luciferase activity 2–3.5-fold compared with the control (Fig 5B, lanes 1–4) Ab-induced transfer-rin–luciferase activity was decreased by the knockdown
of CP2 (Fig 5B, lane 5) Moreover, immunoblot analysis demonstrated that transferrin protein levels were increased by Ab1–42 and Ab25–35 treatment, whereas knockdown of CP2 reduced the transferrin protein level (Fig 5A,B, bottom panel) These findings indicate that Ab (Ab1–42 or Ab25–35) modulates either expression of CP2 or the binding affinity to its target gene However, CP2 protein expression was not chan-ged by Ab treatment (Fig 5A,B)
Taken together, these findings suggest that Ab enhances the ability of CP2 to bind to the transferrin promoter To determine whether Ab increases CP2 binding affinity to the transferrin promoter, HT22 cells were treated with Ab (100 nm Ab1–42 or 20 lm Ab25–
35) for 12 h, and ChIP was performed CP2 binding to the transferrin promoter increased under Ab-treated conditions (Fig 5C,D), and this increase was clearly related to the increased levels of transferrin transcripts
To further confirm the effects of Ab on CP2-dependent precipitation of the transferrin promoter, CP2 shRNA-transfected HT22 cells were incubated with Ab (Ab1–42 and Ab25–35), and a ChIP assay was performed Knockdown of CP2 reduced the amount of trans-ferrin promoter precipitated in the presence of Ab (Fig 5C,D, lane 3) These results show that Ab mark-edly enhances the binding affinity of CP2 towards its target gene promoter
Discussion
Mis-regulation of iron-related proteins changes iron homeostasis and causes ROS generation, which medi-ates neurodegenerative diseases Transferrin is an iron-transporting protein that is involved in the storage and maintenance of iron homeostasis in living organisms
In case studies, transferrin was found to be signifi-cantly up-regulated in the AD frontal cortex compared with normal cases [36] In the present study, we explored the molecular mechanisms by which CP2 reg-ulates transferrin expression in response to Ab To identify possible transcription factors that can modu-late transferrin expression, we used a motif searching program and found several putative transcription fac-tors that can bind to the highly conserved transferrin promoter (Fig 1A) Of these putative transcription factors, we selected CP2, because its binding sites appear most frequently on the transferrin promoter, suggesting that CP2 plays an important role in
1 2 3 4 5 6 7 8 GST (ng) :
A
B
GST-CP2 (ng) :
CP2 Ab :
IgG : cold probe :
– – –
40 80
40 80 80 80 80 – – – – – + – – – – – – – – + – – – – – – – – +
Free probe
shift super shift
N.S
HT22 (TF promoter)
0.0 5.0 10.0
1 2 3
IP with:
Fig 4 CP2 is able to bind to the proximal transferrin promoter
con-sensus element in vitro and in vivo (A) An oligonucleotide probe
covering a 19 bp CP2-dependent enhancer DNA segment of the
transferrin promoter was used for CP2 binding by EMSA
GST-fused recombinant CP2 was purified from E coli using GST beads.
The CP2–DNA complex migrated slowly and the amount increased
in a concentration-dependent manner (lanes 4 and 5) The
exis-tence of CP2 in this slow-migrating complex was verified by adding
CP2 antibody, which caused a supershift (lane 6) Rabbit IgG and
non-labeled probe were included as negative controls (lanes 7 and
8) N.S., non-specifically bound probe (B) Chromatin from mouse
hippocampal cell line HT22 was cross-linked with endogenous CP2.
After precipitation with antibody against CP2 and rabbit IgG,
the transferrin promoter regions containing the CP2 element
were amplified by PCR from the precipitated DNA (upper panel).
The intensity of the transferrin promoter band was quantified by
densitometry (bottom panel).
Trang 7transferrin transcription Indeed, ectopic expression or
knockdown of CP2 modulated transferrin mRNA level
and transferrin–luciferase activity (Fig 2) In luciferase
experiments using transferrin promoter deletion
mutants, we found that the short sequence between
positions )53 and )35 of the transferrin promoter
region was the responding element (Fig 3B) CP2 was
able to bind to this site both in vitro and in vivo
(Fig 4A,B) Furthermore, in the presence of Ab (both
Ab1–42 and Ab25–35), the binding affinity of CP2 to
transferrin promoter was enhanced (Fig 5C,D) and
the transcriptional activity of CP2 to induce transferrin
expression was also up-regulated (Fig 5A,B)
Although CP2 is necessary to regulate the expression
of globins in erythrocytes, it has also been identified as
a possible transcription factor that mediates enhanced transcription of the glycinamide ribonucleotide synthe-tase⁄ aminoimidazole ribonucleotide synthetase ⁄ glycina-mide ribonucleotide transformylase gene, which increases the levels of oxidative stress markers such as
de novo purine biosynthesis and production of hypo-xanthine and hypo-xanthine in Down syndrome-related
AD [32,33] GSK3b is also known as a transcrip-tional target of CP2 [37], and it has been reported that CP2 increases the level of GSK3b transcripts via binding to CP2 binding sites at positions )1 to
TF promoter
A β 25–35 (20 m M ) : CP2 shRNA :
IP : CP2 Ab Input
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6
**
TF-Luc
0 1 2 3 4
5
0 50 100 0 50 100
A β 1–42 (n M ):
CP2 shRNA :
WB: anti-TF
WB: anti-CP2
WB: anti- β-Tubulin
β-tubulin CP2
TF
WB : anti-CP2
WB : anti- β-Tubulin
WB : anti-TF
Aβ 25–35 (m M ) : CP2 shRNA :
1.00 1.49 1.46 2.12
0 1 2 3
5
β-tubulin CP2
TF
**
**
n.s.
IP : CP2 Ab
Input
TF promoter
Aβ 1–42 (100 n M ) :
CP2 shRNA :
0.0 0.5 1.0 1.5 2.0
**
Fig 5 Treatment with Ab modulates the transcriptional activity of CP2 by enhancing its binding affinity to transferrin promoter (A,B) Trans-ferrin reporter vectors and pCMV-b-galactosidase were transiently transfected into HT22 cells, with or without CP2 shRNA vectors Forty-eight hours after transfection, cells were exposed to various concentrations of Ab 1–42 (50 or 100 n M ) and Ab 25–35 (5, 10 and 20 l M ) for 12 h, then luciferase activity was measured (upper panel) Data were normalized using b-galactosidase activity, and are expressed as the relative luciferase units compared to the control Protein levels were verified by Western blotting using antibodies against transferrin, CP2 and b-tubulin (as a loading control) (bottom panels) The band intensity was measured, and transferrin protein levels were normalized relative to b-tubulin (C,D) After transfection and Ab treatment in HT22 cells as described above, cells were cross-linked with 1% formaldehyde and chromatin immunoprecipitations were performed using the CP2 antibody or rabbit IgG as a negative control Binding of CP2 to the transferrin was detected by performing PCR using primers to the highly conserved transferrin promoter site The ChIP experiments were performed several times, and representative gel images are shown The equivalent of 1% of the chromatin used for each ChIP assay was also run on each gel (left panels) After ChIP, the band intensity was measured and the normalized expression level under each condition was calculated relative to the input level (right panels) All data are representative of three independent experiments, and statistical significance was determined using Tukey’s post hoc test (**P < 0.01; n.s., not significant).
Trang 8+10 in the GSK3b promoter [37] Up-regulated
GSK3b expression accelerates tau phosphorylation,
which causes neuronal cell death by formation of
NFTs The level of transferrin was significantly
up-regulated in the frontal cortex of AD patients
com-pared with aged normal cases [36] Although normal
levels of transferrin protein are known to function as
anti-oxidants, it is thought that up-regulation of
trans-ferrin may cause problems associated with iron
over-load, such as hyperferritinemia [38]
It has been reported that CP2 interacts with the
intracellular domain of amyloid precursor protein
(AICD) AICD consists of 50 or 59 amino acids, and
is produced in the cytosol via the action of c-secretase
during the amyloid precursor protein processing
path-way AICD is translocated to the nucleus through
interaction with adaptor protein Fe65 [39], after which
it acts as a co-activator by forming a ternary complex
with Tip60 [40] or CP2 [39] We observed an increase
in transferrin mRNA expression when AICD protein
was co-located with CP2 on the transferrin promoter
(Fig S1A,B) In addition, we found that CP2
modu-lates transferrin expression, with increased binding
affinity to the transferrin promoter in the presence of
Ab (both Ab1–42 and Ab25–35) (Fig 5) However, it is
still not clear how Ab modulates the binding affinity
of CP2 These findings raised the possibility that
accu-mulation of Ab increases the intracellular ROS level
[16], and that increased oxidative stress up-regulates
the activity of c-secretase [41–43] This may increase the
production of AICD and result in up-regulation of the
AICD–CP2 complex Thus, we believe that increased
production of AICD by Ab-related oxidative stress
may stabilize the AICD–Fe65–CP2 ternary complex
and increase the transferrin level by enhancing the
transcriptional activity of CP2 The addition of Ab to
CP2 shRNA-transfected HT22 cells resulted in
increased cell viability (Fig S1C), suggesting that the
target genes of CP2 such as transferrin, GSK3b or
gly-cinamide ribonucleotide synthetase⁄ aminoimidazole
ribonucleotide synthetase⁄ glycinamide ribonucleotide
transformylase may be involved in neurodegeneration
or cell death These results imply that CP2 plays an
important role in Ab-mediated neurodegeneration
Despite intensive studies, there are few therapies
available for AD Accordingly, strategies including
searching for and regulating factors that are involved
in AD pathology and cell survival are required to
improve treatment options In the present study, we
identified CP2 as a transcriptional mediator of
trans-ferrin gene expression in response to Ab in HT22 cells
This is a newly discovered molecular mechanism by
which AD may develop, and suggests a novel possibil-ity for AD treatment and prevention
Experimental procedures
Cell culture and transfections
Human embryonic kidney 293 (HEK293) cells were obtained from the American Type Culture Collection (Manassas, VA, USA) HEK293 and HT22 cells were maintained in Dulbecco’s modified Eagle’s medium supple-mented with 10% fetal bovine serum (Invitrogen, Carlsbad,
CA, USA) and penicillin–streptomycin (50 unitsÆmL)1) The b-amyloid peptides Ab1–42 (A9810) and Ab25–35 (A4559) were purchased from Sigma-Aldrich (St Louis, MO, USA) Transient transfection was performed using Lipofecta-mine 2000 (Invitrogen) with various plasmid DNAs accord-ing to the manufacturer’s instructions
Plasmid constructs
Full-length CP2 was cloned into the FLAG expression vector The human CP2 (hCP2) full-length coding region was ampli-fied from hCP2 cDNA in the human brain library (Clontech, Mountain View, CA) by PCR using primers 5¢-AAGCT
TCAGTATGAT-3¢, which contain HindIII and SalI sites, respectively It was introduced into the pFLAG-CMV2 vector (Sigma-Aldrich), and the presence of the hCP2 clone was veri-fied by DNA sequencing pGEX4T1-CP2 and CP2 shRNA were a gift from C.G Kim (School of Life Sciences, Hanyang University, Seoul, Korea)
Construction of reporter plasmids
As the first step in generating the luciferase reporter con-structs, a human transferrin promoter sequence ()600 to )1) was generated by PCR using the human genomic DNA
CCTCCGGCGCCCC-3¢ (reverse) This PCR product was digested with HindIII, introduced into the pGL4.12 basic vector (Promega, Madison, WI) and verified by DNA sequencing CP2 binding sequence deletion mutants of the transferrin promoter ()82 bp, TF-luc mut1; )131 bp, TF-luc mut2; )188 bp, TF-luc mut3) were prepared by PCR from the wild-type transferrin–luciferase construct (TF-luc WT) using the reverse oligonucleotide primers
5¢-AAGCTTCCACTGATCACCTCA-3¢ (TF-luc mut2) and
and the forward primer given above for the TF-luc WT construct The amplified promoter sequences were cloned into the HindIII sites of the pGL4.12 basic vector and then
Trang 9verified by DNA sequencing using primer 5¢-CTAGCAA
AATAGGCTGTCCC-3¢
Luciferase assay
The HEK293 cells were cultured in 60 mm diameter dishes,
and a total of 600–800 ng DNA including both the
lucifer-ase reporter constructs and pCMV-b-galactosidlucifer-ase together
with FLAG-tagged CP2 and⁄ or CP2 shRNA was
transfect-ed using Lipofectamine 2000 After 48 h of transfection,
cells were lysed in reporter lysis buffer (Promega) The
HT22 cells were cultured in 60 mm diameter dishes and
transfected with the firefly luciferase transferrin reporter
gene (0.1 lg) together with pCMV-b-galactosidase and⁄ or
CP2 shRNA After 48 h of transfection, transfected HT22
cells were treated with Ab Twelve hours after Ab
treat-ment, cells were lysed in reporter lysis buffer Cell extracts
were analyzed with the luciferase reporter assay system
using a Glomax luminometer (Promega) Luciferase
activi-ties were normalized based on the b-galactosidase activity
of the co-transfected vector All transfection experiments
were repeated at least three times independently
Western blotting
For Western blot analysis, HEK293 and HT22 cells were
harvested in cold phosphate-buffered saline and lysed in a
buffer containing 1% Triton X-100, 150 mm NaCl, 50 mm
Tris⁄ HCl, pH 7.5, 0.1% SDS, 1% Nonidet P-40
(Sigma-Aldrich) and 1 mm phenylmethanesulfonyl fluoride Total
lysates were centrifuged at 10 000 g at 4C for 15 min, and
the proteins were electrophoresed by 10% SDS⁄ PAGE and
transferred to a nitrocellulose membrane (Bio-Rad,
Hercu-les, CA, USA) The membrane was blocked with 5% skim
milk in a solution of 20 mm Tris⁄ HCl (pH 7.6), 137 mm
NaCl and 0.1% Tween-20, and incubated with appropriate
dilutions of the primary antibody at room temperature for
3 h Excess primary antibody was removed by sequential
washing, and a 1 : 5000 dilution of the appropriate
horse-radish peroxidase-conjugated secondary antibody was added
to the membrane at room temperature for 1 h The CP2
anti-body was kindly provided by C.G Kim (School of Life
Sci-ences, Hanyang University, Seoul, Korea) The monoclonal
antibody against FLAG (F3165) was purchased from
Sigma-Aldrich Polyclonal antibodies against transferrin (sc-22597)
and b-tubulin (sc-9104) were purchased from Santa Cruz
Biotechnology Inc (Santa Cruz, CA, USA) Western
Blotting was visualized by chemiluminescence using an ECL
system (Santa Cruz Biotechnology Inc.)
RNA preparation and RT-PCR
Total RNAs were extracted from HEK293 and HT22 cells
using Trizol reagent (Invitrogen) The reverse transcription
reaction was performed at 42C for 1 h in a total volume
of 10 lL containing 800 ng RNA, 10 units of avian myelo-blastosis virus reverse transcriptase (Intron Biotechnology Inc., Seoul, Korea) and 100 pmol of oligo(dT) primers The resulting cDNA was used as a template for PCR using 0.2 units of ExTaq according to the manufacturer’s recom-mendations (Takara Biotechnology Inc., Seoul, Korea) PCR conditions were as follows: denaturation at 95C for
3 min, followed by 30 cycles of denaturation at 98C for
10 s, annealing at 55C for 30 s and extension at 72 C for 40 s, and concluding with a final extension at 72C for
10 min The PCR products were separated on a 2% aga-rose gel and visualized by ethidium bromide staining The primers used in PCR were 5¢-CCTGATCCATGGGCTA AGAA-3¢ (transferrin forward primer), 5¢-CGACCGGAA CAAACAAAAGT-3¢ (transferring reverse primer), 5¢-GA GTCAACGGATTTGGTCGT-3¢ (GAPDH forward pri-mer) and 5¢-TTGATTTTGGAGGGATCTCG-3¢ (GAPDH reverse primer) The expression level of GAPDH was used
as an internal control
Electrophoretic mobility shift assays (EMSA)
GST–CP2 fusion proteins and GST proteins were expressed
in Escherichia coli strain BL21 Fusion proteins were puri-fied using glutathione–Sepharose (GE Healthcare, Piscata-way, NJ, USA), and their concentration was determined
by the Bradford assay using Bio-Rad protein assay kit (Bio-Rad, CA, USA) according to the manufacturer’s instruction Single-stranded complementary oligonucleotides were annealed and end-labeled with [c-32P]ATP using T4 polynucleotide kinase The DNA sequences of the oligonu-cleotides corresponding to the conserved CP2 element in the proximal transferrin promoter at positions )63 to )24 are 5¢-TTATTCCATTCCCGGCCTGGGCGGGCTGGGC GCAATCTTT-3¢ (sense) and 5¢-AAAGATTGCGCCCAG
EMSA was performed with 40 or 80 ng of GST or GST-fused CP2 protein in binding buffer (100 mm Tris⁄ HCl, pH 7.5, 10 mm EDTA, 1 m KCl, 1 mm dithiothreitol, 50% glycerol and 100 ngÆlL)1 BSA) For competition or supershift assays, the indicated unlabeled oligonucleotide competitor or CP2 antibody (2 lL) was added 30 min prior
to addition of radiolabeled probe After addition of the radiolabeled probe, the samples were incubated for 30 min
at 30C and loaded on a 5% native polyacrylamide gel in
1· Tris ⁄ acetate ⁄ EDTA (TAE) buffer, electrophoresed, dried and exposed to X-ray film
Chromatin immunoprecipitation (ChIP)
ChIP was performed according to the instructions provided
by Upstate Biotechnology, Inc (Lake Placid, NY) Briefly, HT22 cells treated or untreated with 100 nm Ab1–42 or
20 lm Ab25–35 Twelve hours after Ab treatment, cells were cross-linked with 1% formaldehyde in medium for 15 min
Trang 10at 37C Cells were then washed with ice-cold NaCl ⁄ Piand
resuspended in 200 lL of SDS sample buffer containing a
protease inhibitor mixture The suspension was sonicated
three times for 10 s each with a 1 min cooling period on
ice, and 1% of each sample was retained as the input
frac-tion The chromatin solution was pre-cleared with 20 lL of
protein A–agarose beads blocked with sonicated salmon
sperm DNA for 30 min at 4C The beads were removed,
and the solution was immunoprecipitated overnight with
5 lg of the CP2 antibody at 4C, followed by incubation
with 40 lL of protein A–agarose beads for an additional
1 h at 4C Normal rabbit IgG was used as a negative
con-trol The immune complexes were eluted with 100 lL of
elution buffer (1% SDS and 0.1 m NaHCO3), and
formal-dehyde cross-links were reversed by heating at 65C for
6 h Proteinase K was added to the reaction mixtures,
which were incubated at 45C for 1 h Immunoprecipitated
DNA and control input DNA was purified using the
phe-nol⁄ chloroform extraction method, and then analyzed
by semi-quantitative PCR using the human transferrin
promoter-specific primers 5¢-CGCGATGACAATGGCTG
CATTGTG-3¢ (forward) and 5¢-TGAGCAGCGAGCACA
GTCGGACTC-3¢ (reverse) The PCR conditions were
95C for 3 min, then 98 C for 10 s, 62 C for 30 s and
72C for 50 s for 35 cycles
Statistical analysis
Statistical analysis of variances between two experimental
groups was performed using Tukey’s post hoc comparison
test with Statistical Package for the Social Sciences (SPSS)
version 11.5 All experiments were repeated at least three
times Differences are considered significant at P < 0.01
Acknowledgements
This work was supported by the Mid-career
Researcher Program through National Research
Foun-dation of Korea grants funded by the Korean
govern-ment (grant numbers 2009-0079913 and 2010-0000409)
This work was supported by the Seoul R&BD
Program (grant number 10543) and the BK21 Program
References
1 Albert MS (1996) Cognitive and neurobiologic markers
of early Alzheimer disease Proc Natl Acad Sci USA 93,
13547–13551
2 Selkoe DJ (1999) Translating cell biology into
therapeu-tic advances in Alzheimer’s disease Nature 399, A23–
A31
3 Lovestone S, Reynolds CH, Latimer D, Davis DR,
Anderton BH, Gallo JM, Hanger D, Mulot S,
Marquardt B, Stabel S et al (1994) Alzheimer’s
disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3
in transfected mammalian cells Curr Biol 4, 1077– 1086
4 Litersky JM & Johnson GV (1992) Phosphorylation by cAMP-dependent protein kinase inhibits the degrada-tion of tau by calpain J Biol Chem 267, 1563–1568
5 Feijoo C, Campbell DG, Jakes R, Goedert M & Cuenda A (2005) Evidence that phosphorylation of the microtubule-associated protein Tau by SAPK4⁄ p38delta
at Thr50 promotes microtubule assembly J Cell Sci
118, 397–408
6 Anderton BH, Brion JP, Couck AM, Davis DR, Gallo
JM, Hanger DP, Ladhani K, Latimer DA, Lewis C, Lovestone S et al (1995) Modulation of PHF-like tau phosphorylation in cultured neurones and transfected cells Neurobiol Aging 16, 389–397 discussion 398–402
7 Sperber BR, Leight S, Goedert M & Lee VM (1995) Glycogen synthase kinase-3b phosphorylates tau protein
at multiple sites in intact cells Neurosci Lett 197, 149–153
8 Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S et al (2001) Oxidative damage is the earliest event in Alzheimer disease J Neuropathol Exp Neurol 60, 759–767
9 Markesbery WR (1997) Oxidative stress hypothesis in Alzheimer’s disease Free Radic Biol Med 23, 134–147
10 Smith MA, Rottkamp CA, Nunomura A, Raina AK & Perry G (2000) Oxidative stress in Alzheimer’s disease Biochim Biophys Acta 1502, 139–144
11 Smith CD, Carney JM, Starke-Reed PE, Oliver CN, Stadtman ER, Floyd RA & Markesbery WR (1991) Excess brain protein oxidation and enzyme dysfunction
in normal aging and in Alzheimer disease Proc Natl Acad Sci USA 88, 10540–10543
12 Smith MA, Richey Harris PL, Sayre LM, Beckman JS
& Perry G (1997) Widespread peroxynitrite-mediated damage in Alzheimer’s disease J Neurosci 17, 2653– 2657
13 Gabbita SP, Lovell MA & Markesbery WR (1998) Increased nuclear DNA oxidation in the brain in Alzheimer’s disease J Neurochem 71, 2034–2040
14 Barja G & Herrero A (2000) Oxidative damage to mito-chondrial DNA is inversely related to maximum life span in the heart and brain of mammals FASEB J 14, 312–318
15 Praprotnik D, Smith MA, Richey PL, Vinters HV & Perry G (1996) Plasma membrane fragility in dystrophic neurites in senile plaques of Alzheimer’s disease: an index of oxidative stress Acta Neuropathol 91, 1–5
16 Behl C, Davis JB, Lesley R & Schubert D (1994) Hydrogen peroxide mediates amyloid b protein toxicity Cell 77, 817–827